Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients - A nationwide register-based open cohort study

Osteoporosis International

Volumn 24, Issue 1, 2013, Pages 245-252

  Bondo, L ^a   Eiken, P ^b   Abrahamsen, B ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Adherence; Epidemiology; Hip fracture; Mortality; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PREDNISOLONE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COLLAGEN DISEASE; COMORBIDITY; COMPARATIVE STUDY; DEMENTIA; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN STUDY; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DENMARK; DIPHOSPHONATES; DRUG UTILIZATION; FEMALE; HIP FRACTURES; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; REGISTRIES; SURVIVAL ANALYSIS;

EID: 84872332622     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2024-8     Document Type: Article

References (21)

1. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153-159
2. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fracture and mortality after hip fracture. N Engl J Med 357:1799-1809
3. Todd CJ, Freeman CJ, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, Parker MJ, Payne BV, Rushton N (1995) Differences in mortality after fracture of hip: the East Anglian audit. BMJ 310:904-908
4. Vestergaard P, Rejnmark L, Mosekilde L (2007) Increased mortality in patients with a hip fracture - effect of pre-morbid and postfracture complications. Osteoporos Int 18:1538-1593
5. Cree MW, Juby AG, Carriere KC (2003) Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 14:722-727
6. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-390
7. Kannegaard PN, Van Der Mark S, Eiken P, Abrahamsen B (2010) Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39:203-209
8. Roche JJ, Wenn RT, Sahota O, Moran CG (2005) Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ 331:1374
9. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Nguyen TV, Eisman JA (2011) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006-1014
10. Sambrook PN, Cameron JS, Chen CJ, March LM, Simpson JM, Cumming RG, Seibel MJ (2010) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551-2556
11. Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174-1181
12. Boufous S, Finch CF, Lord SF (2004) Incidence of hip fracture in New South Wales: are our efforts having effect? MJA 180:623-626
13. Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ, Sambrook PN (2010) Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5 year study. J Bone Miner Res 25:866-872
14. Vestergaard P, Rejnmark L, Mosekilde L (2009) Loss of life years after a hip fracture: effects of age and sex. Acta Orthop 80:525-530
15. Szulc P, Maurice C, Marchand F, Delmas PD (2009) Increased bone resorption is associated with higher mortality in community-dwelling men > 50 years of age: the MINOS study. J Bone Miner Res 24:1116-1124
16. Sambrook PN, Chen CJ, March L, Cameron ID, Cumming RG, Lord SR, Simpson JM, Seribel MJ (2006) High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 21:549-555
17. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Picentini P, Rocci L, Manavalan JS, Tonini G, Poccia F (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31-38
18. Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingels J, Postlethwaite AE (2006) Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146:371-380, OK
19. Fraser L, Vogt KN, Adachi JD, Thabane L (2011) Fracture risk associated with continuation versus discontinuation of bisphophonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag 7:157-166
20. Adachi JD, Josse RG, Graham R, Russell G (2011) If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag 7:181-198
21. Curtis JR, Larson JJC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Suzanne J, Safford M, Solomon DH, LaCroix AZ (2011) Placebo adherence, clinical outcomes, and mortality in the Women's Health Initiative Randomized Hormone Therapy trials. Med Care 49:427-435